Expired activity
Please go to the PowerPak homepage and select a course.

Current Trends in Multiple Sclerosis:
Actionable Insights for Pharmacists

Provided by The University of Tennessee College of Pharmacy, in cooperation with ASiM.
Supported by an educational grant from Biogen.


One of the most challenging aspects of effectively managing patients with multiple sclerosis (MS) is personalizing therapy for those who differ in clinical presentations, disease states, therapy response, treatment-related side-effects, and existing comorbidities. While MS is currently incurable, effective and early treatment can reduce functional and neurological symptoms and significantly improve quality of life. The role of pharmacists in all capacities in the management of patients with MS has expanded to incorporate medication management reconciliation, and consulting. Currently available therapies target immune activity, which is most active early in the disease course; thus, initiation of treatment early on is likely to result in greater efficacy and improved outcomes. Despite this, starting treatment immediately after MS is diagnosed is not currently the standard of care.

This archived symposium explores the current landscape of emerging MS therapies, their efficacy, adverse event management, and pharmacoeconomic implications, as well as the role of pharmacists in patient treatment and management. Management strategies for drug-drug interactions and patient comorbidities are developed as well as strategies to identify and address causes of nonadherence. 


This archived symposium will provide pharmacists the most up-to-date information on current and emerging MS therapies so that pharmacists are well-equipped to take on greater roles in medication management, reconciliation, and consulting, to both personalize MS treatment and improve patient outcomes.


This activity is designed for specialty pharmacists. No prerequisites required.


The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. At the conclusion of this activity, the participant should be able to:

  • DISCUSS the rationale for MS treatment initiation, switching, and product discontinuation.
  • DEVELOP management strategies for monitoring disease-modifying therapies, drug-drug interactions, and patient comorbidities as an integral and routine part of MS patient care.
  • IMPLEMENT strategies to identify and address underlying causes of nonadherence and improve treatment compliance.
  • ASSESS pharmacoeconomic implications and specialty pharmacy management of MS therapies.


acpeThe University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application -based program will provide a statement for 1.5 contact hours of credit (0.15 CEUs) and will be available at the completion of the activity. Successfully completing the activity and receiving credit includes: 1) attending the session; 2) watching, listening to, and participating in the educational activity; 3) completing the self-assessment instrument  with a score of at least 70%. UAN:  0064-0000-16-205-H01-P. CE credit will be submitted to the NABP CPE Monitor within 30 days.  It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.

NABP e-PROFILE ID NUMBER: Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: http://www.nabp.net/programs/cpe-monitor/cpe-monitor-service. To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their date and month of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.

Please allow up to 30 days for your credit to appear on CPE Monitor.

Type of Activity: Application

Published: July 15, 2016
Expires: July 15, 2017

Media: Internet

Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 90 minutes


Participants must complete the activity as described above in the Credit Designation Statement. To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of CE credit will be made available immediately. Click on View Certificate and print the CE statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test.


As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:


Jacquelyn Bainbridge, PharmD, FCCP
Professor, Skaggs School of Pharmacy and Pharmaceutical Sciences
Department of Clinical Pharmacy and  Department of Neurology
University of Colorado Anschutz Medical Campus
Aurora, Colorado

Dr Bainbridge reports receiving grants/research support from UCB Pharma and serving on a speakers' bureau for Teva and UCB Pharma.

Sheldon J. Rich, RPh, PhD
President – SJR Associates, LLC
Adjunct Clinical Assistant Professor
University of Michigan
Ann Arbor, Michigan
Adjunct Assistant Professor
Wayne State University
Detroit, Michigan

Dr Rich reports having no relevant financial or advisory relationships with corporate organizations related to this activity.


In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The authors will inform the reader of when they discuss or reference an unapproved, unlabeled, or investigational use of therapeutic agent or biomedical device.


The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.


A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at gfarr@utasip.com. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.


The following is an archived symposium designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, an archived symposium with synced slides and audio, and a CPE post-test, and evaluation. All 3 sections must be completed to receive CPE credit. A statement of credit will be available online immediately following successful completion of the activity.


Please ensure the computer you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible.
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5


  • Preassessment
  • Welcome and Conference Goals
  • MS: The Disease
    Jacquelyn Bainbridge, PharmD, FCCP

  • Current and Emerging MS Pharmacotherapies
    Jacquelyn Bainbridge, PharmD, FCCP

  • Adverse Effects, Comorbidities, and REMS
    Jacquelyn Bainbridge, PharmD, FCCP, and Sheldon J. Rich, RPh, PhD

  • Addressing Nonadherence
    Sheldon J. Rich, RPh, PhD

  • Pharmacoeconomic Considerations
    Sheldon J. Rich, RPh, PhD

  • Concluding Remarks/Question & Answer Session
    Jacquelyn Bainbridge, PharmD, FCCP, and Sheldon J. Rich, RPh, PhD

  •  Postassessment and Evaluation

What you are about to see is a previously recorded live meeting.
Please note that only "home study" credit will be awarded for participating in this archived presentation.

No "live" credits are available.